Premium
Prognostic Indicators in Chemotherapy for Head and Neck Carcinoma: Alkaline Phosphatase Levels
Author(s) -
Katz Arnold E.,
Hong Waun Ki,
Bhutani Rakesh,
Berman Leonard D.,
Blanchard Gordan J.,
Koff Raymond S.,
Shapshay Stanley M.,
Strong M. Stuart
Publication year - 1980
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1002/lary.1980.90.6.924
Subject(s) - bleomycin , alkaline phosphatase , albumin , medicine , chemotherapy , bilirubin , gastroenterology , biopsy , liver biopsy , serum albumin , carcinoma , induction chemotherapy , head and neck , cisplatin , pathology , endocrinology , chemistry , surgery , enzyme , biochemistry
Serum alkaline phosphatase (AP), total bilirubin, total protein, serum albumin, and serum glutamic oxaloacetic transaminase (SGOT) were determined in 55 patients with biopsy proven carcinoma of the head and neck prior to their induction chemotherapy with cis‐platlnum and bleomycin. Of the 55 patients, 40 (73%) exhibited either a complete or partial response (tumor mass decreased by over 50%) to the chemotherapy. Responses were noted more frequently in patients with elevated AP levels. Nine of the 10 patients (90%) with AP levels > 100 mU/m1 experienced a major response; whereas, only 8 of 16 patients (50%) with AP levels < 60 mU/m1 demonstrated a favorable response to the chemotherapeutic agents. The source of the elevated AP levels has not yet been established. Possible sources include liver, bone, kidney, intestinal mucosa, or the tumor itself. Total bilirubin, total protein, serum albumin, and SGOT levels did not differentiate the responders from the non‐responders as accurately as did the AP levels.